Literature DB >> 25850966

Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders.

Alex J Brewer1, David A Nielsen, Catherine J Spellicy, Sara C Hamon, Justin Gingrich, Daisy G Y Thompson-Lake, Ellen M Nielsen, James J Mahoney, Thomas R Kosten, Thomas F Newton, Richard De La Garza.   

Abstract

OBJECTIVE: The aim of this study was to identify gene variants of DAT1 (SLC6A3) that modulate subjective responses to acute cocaine exposure.
METHODS: Non-treatment-seeking volunteers (n=66) with cocaine use disorders received a single bolus infusion of saline and cocaine (40 mg, intravenous) in a randomized order. Subjective effects were assessed with visual analog scales administered before (-15 min) and up to 20 min after infusion. Ratings of subjective effects were normalized to baseline, and saline infusion values were subtracted. Data were analyzed using repeated measures analysis of variance. DNA from the participants was genotyped for the DAT1 intron 8 (rs3836790) and 3'-untranslated region (rs28363170) variable number of tandem repeats.
RESULTS: Participants were mostly male (∼80%) and African American (∼70%). No differences were found among drug use variables between groups for either polymorphism. Carriers of the 9-allele of the DAT1 3'-untranslated region (9,9 and 9,10) exhibited greater responses to cocaine for 'high', 'any drug effect', 'anxious', and 'stimulated' (all P-values<0.001) compared with individuals homozygous for the 10-allele. For the intron 8 polymorphism, individuals homozygous for the 6-allele exhibited greater responses for 'anxious' compared with carriers of the 5-allele (P<0.001). Individuals possessing the genotype pattern of 10,10 and at least one 5-allele reported lower responses to 'good effects', 'bad effects', 'depressed', and 'anxious' (all P-values<0.01).
CONCLUSION: The data presented here show for the first time support for the hypothesis that genetic differences in DAT1 contribute to the variation in subjective responses to cocaine among participants with cocaine use disorders.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25850966      PMCID: PMC4414865          DOI: 10.1097/FPC.0000000000000137

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  41 in total

1.  Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531.

Authors:  J R Wendland; B J Martin; M R Kruse; K-P Lesch; D L Murphy
Journal:  Mol Psychiatry       Date:  2006-03       Impact factor: 15.992

Review 2.  A qualitative and quantitative review of cocaine-induced craving: the phenomenon of priming.

Authors:  James J Mahoney; Ari D Kalechstein; Richard De La Garza; Thomas F Newton
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-01-31       Impact factor: 5.067

Review 3.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

4.  The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans.

Authors:  D Martinez; J Gelernter; A Abi-Dargham; C H van Dyck; L Kegeles; R B Innis; M Laruelle
Journal:  Neuropsychopharmacology       Date:  2001-05       Impact factor: 7.853

5.  Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue.

Authors:  Keeley J Brookes; Benjamin M Neale; Karen Sugden; Nadeem Khan; Philip Asherson; Ursula M D'Souza
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-12-05       Impact factor: 3.568

6.  Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity.

Authors:  E E Forbes; S M Brown; M Kimak; R E Ferrell; S B Manuck; A R Hariri
Journal:  Mol Psychiatry       Date:  2007-09-25       Impact factor: 15.992

7.  DAT genotype modulates brain and behavioral responses elicited by cigarette cues.

Authors:  Teresa R Franklin; Falk W Lohoff; Ze Wang; Nathan Sciortino; Derek Harper; Yin Li; Will Jens; Jeffrey Cruz; Kyle Kampman; Ron Ehrman; Wade Berrettini; John A Detre; Charles P O'Brien; Anna Rose Childress
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

8.  Variation in dopamine genes influences responsivity of the human reward system.

Authors:  Jean-Claude Dreher; Philip Kohn; Bhaskar Kolachana; Daniel R Weinberger; Karen Faith Berman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-22       Impact factor: 11.205

9.  A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample.

Authors:  Camila Guindalini; Mark Howard; Kate Haddley; Ronaldo Laranjeira; David Collier; Nik Ammar; Ian Craig; Colin O'Gara; Vivian J Bubb; Tiffany Greenwood; John Kelsoe; Phil Asherson; Robin M Murray; Adauto Castelo; John P Quinn; Homero Vallada; Gerome Breen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

10.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.

Authors:  Dawn D Han; Howard H Gu
Journal:  BMC Pharmacol       Date:  2006-03-03
View more
  10 in total

1.  Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence.

Authors:  Shabnam Azadeh; Brian P Hobbs; Liangsuo Ma; David A Nielsen; F Gerard Moeller; Veerabhadran Baladandayuthapani
Journal:  Neuroimage       Date:  2015-10-17       Impact factor: 6.556

2.  Genetic moderation of cocaine subjective effects by variation in the TPH1, TPH2, and SLC6A4 serotonin genes.

Authors:  Michelle A Patriquin; Sara C Hamon; Mark J Harding; Ellen M Nielsen; Thomas F Newton; Richard De La Garza; David A Nielsen
Journal:  Psychiatr Genet       Date:  2017-10       Impact factor: 2.458

3.  Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction.

Authors:  June P Kampangkaew; Catherine J Spellicy; Ellen M Nielsen; Mark J Harding; An Ye; Sara C Hamon; Thomas R Kosten; David A Nielsen
Journal:  Am J Addict       Date:  2019-05-14

4.  Methylation of the serotonin transporter gene moderates the depressive subjective effect of cocaine.

Authors:  Riley B Longtain; David P Graham; Mark J Harding; Richard De La Garza Ii; David A Nielsen
Journal:  Behav Brain Res       Date:  2021-11-16       Impact factor: 3.332

5.  The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals.

Authors:  Daryl Shorter; David A Nielsen; Sara C Hamon; Ellen M Nielsen; Thomas R Kosten; Thomas F Newton; Richard De La Garza
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

6.  No Influence of Dopamine System Gene Variations on Acute Effects of MDMA.

Authors:  Patrick Vizeli; Matthias E Liechti
Journal:  Front Psychiatry       Date:  2019-10-24       Impact factor: 4.157

7.  Associations Among Internet Addiction, Genetic Polymorphisms, Family Functioning, and Psychopathological Risk: Cross-Sectional Exploratory Study.

Authors:  Luca Cerniglia; Silvia Cimino; Eleonora Marzilli; Esterina Pascale; Renata Tambelli
Journal:  JMIR Ment Health       Date:  2020-12-24

8.  The role of the SLC6A3 3' UTR VNTR in nicotine effects on cognitive, affective, and motor function.

Authors:  Rebekka Schröder; Martin Reuter; Kaja Faßbender; Thomas Plieger; Jessie Poulsen; Simon S Y Lui; Raymond C K Chan; Ulrich Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2021-12-02       Impact factor: 4.530

Review 9.  Neurochemical changes in basal ganglia affect time perception in parkinsonians.

Authors:  Francisco Magalhães; Kaline Rocha; Victor Marinho; Jéssica Ribeiro; Thomaz Oliveira; Carla Ayres; Thalys Bento; Francisca Leite; Daya Gupta; Victor Hugo Bastos; Bruna Velasques; Pedro Ribeiro; Marco Orsini; Silmar Teixeira
Journal:  J Biomed Sci       Date:  2018-03-19       Impact factor: 8.410

10.  High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.

Authors:  Mark Moran; Kenneth Blum; Jessica Valdez Ponce; Lisa Lott; Marjorie C Gondré-Lewis; Sampada Badgaiyan; Raymond Brewer; B William Downs; Philip Fynman; Alexander Weingarten; Jean Lud Cadet; David E Smith; David Baron; Panayotis K Thanos; Edward J Modestino; Rajendra D Badgaiyan; Igor Elman; Mark S Gold
Journal:  Mol Neurobiol       Date:  2021-03-08       Impact factor: 5.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.